前列腺癌免疫治疗中癌症疫苗的研究进展  

Advances in cancer vaccines for immunotherapy of prostate cancer

作　　者：靳通通 周川[1] 赵磊 董旭 周逢海 JIN Tongtong;ZHOU Chuan;ZHAO Lei;DONG Xu;ZHOU Fenghai(First School of Clinical Medicine,Lanzhou University,Lanzhou 730000;Department of Urology,Gansu Provincial People’s Hospital,Lanzhou 730000,China)

机构地区：[1]兰州大学第一临床医学院,兰州730000 [2]甘肃省人民医院泌尿外科,兰州730000

出　　处：《中南大学学报（医学版）》2023年第1期148-156,共9页Journal of Central South University ：Medical Science

基　　金：甘肃省科技计划(21YF5FA016)。

摘　　要：前列腺癌是目前威胁老年男性生命健康最常见的恶性肿瘤之一。近年来,以激活抗癌宿主免疫细胞达到杀伤肿瘤效果的免疫治疗成为前列腺癌治疗的一个新的研究方向。癌症疫苗作为免疫治疗的一个重要组成部分,在恶性肿瘤的精准治疗中具有独特的地位。前列腺癌疫苗主要有单核细胞疫苗、树突状细胞疫苗、病毒疫苗、多肽疫苗和DNA/mRNA疫苗等。其中,Sipuleucel-T作为基于单核细胞的癌症疫苗,是目前唯一获得美国食品药品监督管理局批准的前列腺癌治疗性疫苗,在推动前列腺癌免疫治疗的发展中具有独特的地位和作用。然而,由于SipuleucelT自身的局限性,其尚未被广泛采用。同时,由于免疫治疗的复杂性和前列腺癌的特殊性,其余的前列腺癌疫苗并未在大型随机Ⅱ期和Ⅲ期试验中表现出良好的临床获益,仍需进一步深入研究。Prostate cancer is currently one of the most common malignancies that endanger the lives and health of elderly men. In recent years, immunotherapy, which exploits the activation of anti-cancer host immune cells to accomplish tumor-killing effects, has emerged as a new study avenue in the treatment of prostate cancer. As an important component of immunotherapy, cancer vaccines have a unique position in the precision treatment of malignant tumors. Monocyte cell vaccines, dendritic cell vaccines, viral vaccines, peptide vaccines, and DNA/mRNA vaccines are the most often used prostate cancer vaccines. Among them, Sipuleucel-T, as a monocyte cell-based cancer vaccine, is the only FDA-approved therapeutic vaccine for prostate cancer, and has a unique position and role in advancing the development of immunotherapy for prostate cancer. However, due to its own limitations, Sipuleucel-T has not been widely adopted. Meanwhile, owing to the complexity of immunotherapy and the specificity of prostate cancer, the remaining prostate cancer vaccines have not shown good clinical benefit in large randomized phase Ⅱ and phase Ⅲ trials, and further in-depth studies are still needed.

关 键 词：前列腺癌 癌症疫苗 SIPULEUCEL-T 免疫治疗 

分 类 号：R737.25[医药卫生—肿瘤]